The role of APOE on lipid homeostasis and inflammation in normal brains

Raber, 2004, ApoE genotype accounts for the vast majority of AD risk and AD pathology, Neurobiol. Aging., 25, 641, 10.1016/j.neurobiolaging.2003.12.023

Jansen, 2015, Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis, JAMA., 313, 1924, 10.1001/jama.2015.4668

Liu, 2013, Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy, Nat. Rev. Neurol., 9, 106, 10.1038/nrneurol.2012.263

Malik, 2015, Genetics ignite focus on microglial inflammation in Alzheimer's disease, Mol. Neurodegener., 10, 52, 10.1186/s13024-015-0048-1

Sullivan, 1997, Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis, J. Biol. Chem., 272, 17972, 10.1074/jbc.272.29.17972

Zhu, 2012, APOE genotype alters glial activation and loss of synaptic markers in mice, Glia., 60, 559, 10.1002/glia.22289

Rodriguez, 2014, Human APOE4 increases microglia reactivity at Aβ plaques in a mouse model of Aβ deposition, J. Neuroinflammation., 11, 111, 10.1186/1742-2094-11-111

Mannix, 2011, Age-dependent effect of apolipoprotein E4 on functional outcome after controlled cortical impact in mice, J. Cereb. Blood Flow Metab., 31, 351, 10.1038/jcbfm.2010.99

Tu, 2009, APOE 4 polymorphism results in early cognitive deficits in an EAE model, Biochem. Biophys. Res. Commun., 384, 466, 10.1016/j.bbrc.2009.04.153

Lynch, 2003, APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response, J. Biol. Chem., 278, 48529, 10.1074/jbc.M306923200

Lynch, 2005, A novel therapeutic derived from apolipoprotein E reduces brain inflammation and improves outcome after closed head injury, Exp. Neurol., 192, 109, 10.1016/j.expneurol.2004.11.014

James, 2009, Pharmacogenomic effects of apolipoprotein E on intracerebral hemorrhage, Stroke., 40, 632, 10.1161/STROKEAHA.108.530402

Wang, 2013, Apolipoprotein E mimetic peptides improve outcome after focal ischemia, Exp. Neurol., 241, 67, 10.1016/j.expneurol.2012.11.027

Guo, 2004, A dual role for apolipoprotein E in neuroinflammation: anti- and pro-inflammatory activity, J. Mol. Neurosci., 23, 205, 10.1385/JMN:23:3:205

Vitek, 2009, APOE genotype-specific differences in the innate immune response, Neurobiol. Aging., 30, 1350, 10.1016/j.neurobiolaging.2007.11.014

Pocivavsek, 2009, Low-density lipoprotein receptors regulate microglial inflammation through c-Jun N-terminal kinase, Glia., 57, 444, 10.1002/glia.20772

Pocivavsek, 2009, Microglial low-density lipoprotein receptor-related protein 1 modulates c-Jun N-terminal kinase activation, J. Neuroimmunol., 214, 25, 10.1016/j.jneuroim.2009.06.010

Baitsch, 2011, Apolipoprotein E induces antiinflammatory phenotype in macrophages, Arterioscler. Thromb. Vasc. Biol., 31, 1160, 10.1161/ATVBAHA.111.222745

Pocivavsek, 2009, Inhibition of c-Jun N-terminal kinase increases apoE expression in vitro and in vivo, Biochem. Biophys. Res. Commun., 387, 516, 10.1016/j.bbrc.2009.07.048

Pitas, 1987, Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain, J. Biol. Chem., 262, 14352, 10.1016/S0021-9258(18)47945-8

Karch, 2015, Alzheimer's disease risk genes and mechanisms of disease pathogenesis, Biol. Psychiatry., 77, 43, 10.1016/j.biopsych.2014.05.006

Harold, 2009, Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, Nat. Genet., 41, 1088, 10.1038/ng.440

Lambert, 2009, Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease, Nat. Genet., 41, 1094, 10.1038/ng.439

Jun, 2010, Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes, Arch. Neurol., 67, 1473, 10.1001/archneurol.2010.201

Borghini, 1995, Characterization of subpopulations of lipoprotein particles isolated from human cerebrospinal fluid, Biochim. Biophys. Acta., 1255, 192, 10.1016/0005-2760(94)00232-N

Rebeck, 1998, Structure and functions of human cerebrospinal fluid lipoproteins from individuals of different APOE genotypes, Exp. Neurol., 149, 175, 10.1006/exnr.1997.6710

White, 2001, Alterations in ApoE and ApoJ in relation to degeneration and regeneration in a mouse model of entorhinal cortex lesion, Exp. Neurol., 169, 307, 10.1006/exnr.2001.7655

Fagan, 1998, Evidence for normal aging of the septo-hippocampal cholinergic system in apoE (−/−) mice but impaired clearance of axonal degeneration products following injury, Exp. Neurol., 151, 314, 10.1006/exnr.1998.6818

Koldamova, 2014, ATP-binding cassette transporter A1: from metabolism to neurodegeneration, Neurobiol. Dis., 72 Pt. A, 13, 10.1016/j.nbd.2014.05.007

Hirsch-Reinshagen, 2004, Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain, J. Biol. Chem., 279, 41197, 10.1074/jbc.M407962200

Wahrle, 2005, Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease, J. Biol. Chem., 280, 43236, 10.1074/jbc.M508780200

Michikawa, 2000, Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture, J. Neurochem., 74, 1008, 10.1046/j.1471-4159.2000.0741008.x

Minagawa, 2009, Mechanism underlying apolipoprotein E (ApoE) isoform-dependent lipid efflux from neural cells in culture, J. Neurosci. Res., 87, 2498, 10.1002/jnr.22073

Boehm-Cagan, 2014, Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene, J. Neurosci., 34, 7293, 10.1523/JNEUROSCI.5198-13.2014

Boehm-Cagan, 2016, ABCA1 agonist reverses the apoE4-driven cognitive and brain pathologies, J. Alzheimers Dis., 54, 1219, 10.3233/JAD-160467

Hu, 2015, Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Aβ metabolism in apoE4-targeted replacement mice, Mol. Neurodegener., 10, 6, 10.1186/s13024-015-0001-3

Dodart, 2005, Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease, Proc. Natl. Acad. Sci. USA., 102, 1211, 10.1073/pnas.0409072102

Heinsinger, 2016, Apolipoprotein E genotype affects size of apoE complexes in cerebrospinal fluid, J. Neuropathol. Exp. Neurol., 75, 918, 10.1093/jnen/nlw067

Yassine, 2016, ABCA1-mediated cholesterol efflux capacity to cerebrospinal fluid is reduced in patients with mild cognitive impairment and Alzheimer's disease, J. Am. Heart Assoc., 5, e002886, 10.1161/JAHA.115.002886

Hanson, 2013, Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial, JAMA Neurol., 70, 972, 10.1001/jamaneurol.2013.396

Harris-White, 2005, Low density lipoprotein receptor-related proteins (LRPs), Alzheimer's and cognition, Curr. Drug Targets CNS Neurol. Disord., 4, 469, 10.2174/156800705774322102

Nathan, 1994, Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro, Science., 264, 850, 10.1126/science.8171342

Teter, 1999, Human apolipoprotein E isoform-specific differences in neuronal sprouting in organotypic hippocampal culture, J. Neurochem., 73, 2613, 10.1046/j.1471-4159.1999.0732613.x

Mauch, 2001, CNS synaptogenesis promoted by glia-derived cholesterol, Science., 294, 1354, 10.1126/science.294.5545.1354

Yeh, 2016, TREM2 binds to apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates uptake of amyloid-beta by microglia, Neuron., 91, 328, 10.1016/j.neuron.2016.06.015

Atagi, 2015, Apolipoprotein E is a ligand for triggering receptor expressed on myeloid cells 2 (TREM2), J. Biol. Chem., 290, 26043, 10.1074/jbc.M115.679043

Jonsson, 2013, Variant of TREM2 associated with the risk of Alzheimer's disease, N. Engl. J. Med., 368, 107, 10.1056/NEJMoa1211103

Mulder, 2014, Apolipoproteins E and J interfere with amyloid-beta uptake by primary human astrocytes and microglia in vitro, Glia., 62, 493, 10.1002/glia.22619

Cole, 1999, Lipoprotein effects on Abeta accumulation and degradation by microglia in vitro, J. Neurosci. Res., 57, 504, 10.1002/(SICI)1097-4547(19990815)57:4<504::AID-JNR10>3.0.CO;2-H

Bell, 2007, Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system, J. Cereb. Blood Flow Metab., 27, 909, 10.1038/sj.jcbfm.9600419

Ignatius, 1986, Expression of apolipoprotein E during nerve degeneration and regeneration, Proc. Natl. Acad. Sci. USA., 83, 1125, 10.1073/pnas.83.4.1125

Washington, 2016, The effect of the APOE4 gene on accumulation of Aβ40 after brain injury cannot be reversed by increasing apoE4 protein, J. Neuropathol. Exp. Neurol., 10.1093/jnen/nlw049

Arendt, 1997, Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein epsilon 4 allele, J. Neurosci., 17, 516, 10.1523/JNEUROSCI.17-02-00516.1997

Ringheim, 2006, Brain inflammation, cholesterol, and glutamate as interconnected participants in the pathology of Alzheimer's disease, Curr. Pharm. Des., 12, 719, 10.2174/138161206775474215

Courtney, 2016, LXR regulation of brain cholesterol: from development to disease, Trends Endocrinol. Metab., 27, 404, 10.1016/j.tem.2016.03.018

Castellano, 2011, Human apoE isoforms differentially regulate brain amyloid-β peptide clearance, Sci. Transl. Med., 3, 89ra57, 10.1126/scitranslmed.3002156

Cruchaga, 2012, Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease, Hum. Mol. Genet., 21, 4558, 10.1093/hmg/dds296

Sullivan, 2011, Reduced levels of human apoE4 protein in an animal model of cognitive impairment, Neurobiol. Aging., 32, 791, 10.1016/j.neurobiolaging.2009.05.011

Riddell, 2008, Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels, J. Neurosci., 28, 11445, 10.1523/JNEUROSCI.1972-08.2008

Harris, 2003, Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice, Proc. Natl. Acad. Sci. USA., 100, 10966, 10.1073/pnas.1434398100

Bien-Ly, 2011, C-terminal-truncated apolipoprotein (apo) E4 inefficiently clears amyloid-beta (Abeta) and acts in concert with Abeta to elicit neuronal and behavioral deficits in mice, Proc. Natl. Acad. Sci. USA., 108, 4236, 10.1073/pnas.1018381108

Brecht, 2004, Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice, J. Neurosci., 24, 2527, 10.1523/JNEUROSCI.4315-03.2004

Huang, 2001, Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons, Proc. Natl. Acad. Sci. USA., 98, 8838, 10.1073/pnas.151254698

Wernette-Hammond, 1989, Glycosylation of human apolipoprotein E. The carbohydrate attachment site is threonine 194, J. Biol. Chem., 264, 9094, 10.1016/S0021-9258(18)81907-X

DiBattista, 2016, Identification and modification of amyloid-independent phenotypes of APOE4 mice, Exp. Neurol., 280, 97, 10.1016/j.expneurol.2016.04.014

Tolar, 1999, Truncated apolipoprotein E (ApoE) causes increased intracellular calcium and may mediate ApoE neurotoxicity, J. Neurosci., 19, 7100, 10.1523/JNEUROSCI.19-16-07100.1999

Teter, 2002, Defective neuronal sprouting by human apolipoprotein E4 is a gain-of-negative function, J. Neurosci. Res., 68, 331, 10.1002/jnr.10221

Rodriguez, 2013, Young APOE4 targeted replacement mice exhibit poor spatial learning and memory, with reduced dendritic spine density in the medial entorhinal cortex, Learn. Mem., 20, 256, 10.1101/lm.030031.112

Bour, 2008, Middle-aged human apoE4 targeted-replacement mice show retention deficits on a wide range of spatial memory tasks, Behav. Brain Res., 193, 174, 10.1016/j.bbr.2008.05.008

Grootendorst, 2005, Human apoE targeted replacement mouse lines: h-apoE4 and h-apoE3 mice differ on spatial memory performance and avoidance behavior, Behav. Brain Res., 159, 1, 10.1016/j.bbr.2004.09.019

Knoferle, 2014, Apolipoprotein E4 produced in GABAergic interneurons causes learning and memory deficits in mice, J. Neurosci., 34, 14069, 10.1523/JNEUROSCI.2281-14.2014

Dumanis, 2009, ApoE4 decreases spine density and dendritic complexity in cortical neurons in vivo, J. Neurosci., 29, 15317, 10.1523/JNEUROSCI.4026-09.2009

Wang, 2005, Human apoE4-targeted replacement mice display synaptic deficits in the absence of neuropathology, Neurobiol. Dis., 18, 390, 10.1016/j.nbd.2004.10.013

Gillespie, 2016, Apolipoprotein E4 causes age-dependent disruption of slow gamma oscillations during hippocampal sharp-wave ripples, Neuron., 90, 740, 10.1016/j.neuron.2016.04.009

Leung, 2012, Apolipoprotein E4 causes age- and sex-dependent impairments of hilar GABAergic interneurons and learning and memory deficits in mice, PLoS One., 7, e53569, 10.1371/journal.pone.0053569

Klein, 2014, Altered neurotransmission in the lateral amygdala in aged human apoE4 targeted replacement mice, Neurobiol. Aging., 35, 2046, 10.1016/j.neurobiolaging.2014.02.019

Klein, 2010, Progressive loss of synaptic integrity in human apolipoprotein E4 targeted replacement mice and attenuation by apolipoprotein E2, Neuroscience., 171, 1265, 10.1016/j.neuroscience.2010.10.027

Dolejší, 2016, Apolipoprotein E4 reduces evoked hippocampal acetylcholine release in adult mice, J. Neurochem., 136, 503, 10.1111/jnc.13417

Ji, 2003, Apolipoprotein E isoform-specific regulation of dendritic spine morphology in apolipoprotein E transgenic mice and Alzheimer's disease patients, Neuroscience., 122, 305, 10.1016/j.neuroscience.2003.08.007

Dumanis, 2013, APOE genotype affects the pre-synaptic compartment of glutamatergic nerve terminals, J. Neurochem., 124, 4, 10.1111/j.1471-4159.2012.07908.x

Gilat-Frenkel, 2014, Involvement of the Apoer2 and Lrp1 receptors in mediating the pathological effects of ApoE4 in vivo, Curr. Alzheimer Res., 11, 549, 10.2174/1567205010666131119232444

Caselli, 2004, Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele, Neurology., 62, 1990, 10.1212/01.WNL.0000129533.26544.BF

Acevedo, 2010, Apolipoprotein E4 and sex affect neurobehavioral performance in primary school children, Pediatr. Res., 67, 293, 10.1203/PDR.0b013e3181cb8e68

Filippini, 2009, Anatomically-distinct genetic associations of APOE epsilon4 allele load with regional cortical atrophy in Alzheimer's disease, Neuroimage., 44, 724, 10.1016/j.neuroimage.2008.10.003

Rusted, 2013, APOE e4 polymorphism in young adults is associated with improved attention and indexed by distinct neural signatures, Neuroimage., 65, 364, 10.1016/j.neuroimage.2012.10.010

Green, 2014, A combined effect of two Alzheimer's risk genes on medial temporal activity during executive attention in young adults, Neuropsychologia., 56, 1, 10.1016/j.neuropsychologia.2013.12.020

Borghesani, 2008, Altered medial temporal lobe responses during visuospatial encoding in healthy APOE*4 carriers, Neurobiol. Aging., 29, 981, 10.1016/j.neurobiolaging.2007.01.012

Kunz, 2015, Reduced grid-cell-like representations in adults at genetic risk for Alzheimer's disease, Science., 350, 430, 10.1126/science.aac8128

Dean, 2014, Brain differences in infants at differential genetic risk for late-onset Alzheimer disease: a cross-sectional imaging study, JAMA Neurol., 71, 11, 10.1001/jamaneurol.2013.4544

Knickmeyer, 2014, Common variants in psychiatric risk genes predict brain structure at birth, Cereb. Cortex., 24, 1230, 10.1093/cercor/bhs401

Di Battista, 2016, Alzheimer's disease genetic risk factor APOE-ε4 also affects normal brain function, Curr. Alzheimer Res., 13, 1200, 10.2174/1567205013666160401115127

Matura, 2014, Differential effects of the ApoE4 genotype on brain structure and function, Neuroimage., 89, 81, 10.1016/j.neuroimage.2013.11.042

O'Dwyer, 2012, Reduced hippocampal volume in healthy young ApoE4 carriers: an MRI study, PLoS One., 7, e48895, 10.1371/journal.pone.0048895

Stevens, 2014, A gene-brain-cognition pathway for the effect of an Alzheimers risk gene on working memory in young adults, Neuropsychologia., 61, 143, 10.1016/j.neuropsychologia.2014.06.021

Han, 2008, Revision of the apolipoprotein E compensatory mechanism recruitment hypothesis, Alzheimers Dement., 4, 251, 10.1016/j.jalz.2008.02.006

Laskowitz, 2007, Apolipoprotein E and neurological disease: therapeutic potential and pharmacogenomic interactions, Pharmacogenomics., 8, 959, 10.2217/14622416.8.8.959

Cornelius, 2004, Aspirin, NSAIDs, risk of dementia, and influence of the apolipoprotein E epsilon 4 allele in an elderly population, Neuroepidemiology., 23, 135, 10.1159/000075957

Lindsay, 2002, Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging, Am. J. Epidemiol., 156, 445, 10.1093/aje/kwf074

Stewart, 1997, Risk of Alzheimer's disease and duration of NSAID use, Neurology., 48, 626, 10.1212/WNL.48.3.626

Zandi, 2002, Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study, Neurology., 59, 880, 10.1212/WNL.59.6.880

in't Veld, 2001, Antihypertensive drugs and incidence of dementia: the Rotterdam Study, Neurobiol. Aging., 22, 407, 10.1016/S0197-4580(00)00241-4

Pasqualetti, 2009, A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease, Aging Clin. Exp. Res., 21, 102, 10.1007/BF03325217

Breitner, 2011, Extended results of the Alzheimer's disease anti-inflammatory prevention trial, Alzheimers Dement., 7, 402, 10.1016/j.jalz.2010.12.014

Hayden, 2007, Does NSAID use modify cognitive trajectories in the elderly? The Cache County Study, Neurology., 69, 275, 10.1212/01.wnl.0000265223.25679.2a

Szekely, 2008, NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type, Neurology., 70, 17, 10.1212/01.wnl.0000284596.95156.48

Yip, 2005, Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE study, BMC Geriatr., 5, 2, 10.1186/1471-2318-5-2

Hong, 2014, Liver X receptors in lipid metabolism: opportunities for drug discovery, Nat. Rev. Drug Discov., 13, 433, 10.1038/nrd4280

Eckert, 2007, Regulation of central nervous system cholesterol homeostasis by the liver X receptor agonist TO-901317, Neurosci. Lett., 423, 47, 10.1016/j.neulet.2007.05.063

Donkin, 2010, ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice, J. Biol. Chem., 285, 34144, 10.1074/jbc.M110.108100

Fitz, 2014, Improvement of memory deficits and amyloid-β clearance in aged APP23 mice treated with a combination of anti-amyloid-β antibody and LXR agonist, J. Alzheimers Dis., 41, 535, 10.3233/JAD-132789

Sandoval-Hernández, 2015, Role of liver X receptor in AD pathophysiology, PLoS One., 10, e0145467, 10.1371/journal.pone.0145467

Cramer, 2012, ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models, Science., 335, 1503, 10.1126/science.1217697

Corona, 2016, ABCA1 is necessary for bexarotene-mediated clearance of soluble amyloid beta from the hippocampus of APP/PS1 mice, J. Neuroimmune Pharmacol., 11, 61, 10.1007/s11481-015-9627-8

Sperling, 2014, The evolution of preclinical Alzheimer's disease: implications for prevention trials, Neuron., 84, 608, 10.1016/j.neuron.2014.10.038